Skip to NavigationSkip to content

pharmaceuticals

Royal Pharmaceutical Society in Scotland says contingency plans do not mitigate risk of no-deal Brexit

Image Credit: https://commons.wikimedia.org/wiki/File:Scottish_Parliament_building,_Holyrood.jpg

The Royal Pharmaceutical Society (RPS) in Scotland has raised concerns that the Government’s contingency plans do not eliminate the risks of Brexit.

The RPS has warned that “several challenges remain” as they suggested that the Scottish and UK Government’s contingency plans do “not eliminate these risks.”

Speaking to Holyrood, Alex MacKinnon, the Director of the RPS in Scotland said: “We have sought to engage constructively with the UK Government on measures to mitigate the risks associated. However, several challenges remain.

One third of Brits stockpile drugs

A third (33%) of brits stockpile medicines, according to new research from Co-op Health.

One in three British people never get rid of leftover medicines while another third have used medicines past their expiry date.

Of those who admitted to using out-of-date medicines almost half (48%) said they did not realise the medicines had expired, one quarter (25%) presumed it would still be safe to take, and more than a tenth (13%) bought the medicines before they needed to use them.

Very high concentrations of pharmaceuticals found in animals in Australian streams

More than 60 different pharmaceutical compounds were detected in aquatic invertebrate larvae and riparian predators in six streams near Melbourne, Australia, according to a paper published in the journal Nature Communications.

Meanwhile predators who feed on aquatic invertebrates, such as platypus and brown trout, may inadvertently consume around a half of the daily human therapeutic dose of drugs such as antidepressants, through feeding on their prey.

FDA approves Agios' oral leukaemia treatment Tibsovo

The oral leukaemia treatment Tibsovo (ivosidenib) produced by Massachusetts-based Agios Pharmaceuticals has been approved for treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with a defective IDH1 gene in the United States.

The FDA approved the Cambridge-based drug makers AML pill for use in treating the rapidly progressing bone marrow cancer. The National Cancer Institute at the National Institute of Health estimated that 19,520 people will be diagnosed with AML this year while 10,670 will die from the disease.

Top Ten most popular articles on Pharmafile.com this week

As we move into November, we bring you another run down of the top ten most popular articles on Pharmafile.com this week.

Novartis' has revealed the data behind the approval of its CAR-T therapy Kymriah as it became the first-ever such treatment approved by the FDA. Gilead entered the fray weeks later with its own approval, and the CAR-T space is now heating up. We delved into this area for an in-depth feature exploring the huge promise it presents.

Top Ten most popular articles on Pharmafile.com this week

It's been another packed week in the industry, with one of the biggest takeaways being that childhood obesity has rocketed up ten-fold over the last 40 years.

Another shocking discovery this week revealed that, of 103 UK companies, pharma giant GlaxoSmithKline was the worst in terms of criteria for good governance, according to a report by the Institute of Directors.

Strong IBS and constipation Phase 3 data sends Ardelyx shares rocketing 60%

Ardelyx has confirmed that its NHE3 inhibitor tenapanor met all its primary and secondary endpoints in the study of its treatment efficacy against irritable bowel syndrome and constipation (IBS-C). Based on the positive results the therapy has garnered, Ardelyx plans to file for US approval of the drug in the second half of 2018.

Harnessing the power of the immune system

Published on 09/10/17 at 10:55am

Dr Áine McCarthy, Senior Science Information Officer at Cancer Research UK, discusses the latest efforts to further understand the immunotherapies that have done so much for cancer treatment in recent years, and how they can be pushed to achieve even more.

China to accelerate drug approvals with overseas trial data

In a bid to speed up access to medicines for patients, China has revealed it intends to incorporate data from clinical trials conducted overseas into its approval process for new drugs, meaning international manufacturers and patients alike could face less delays in the world’s second-largest pharmaceutical market.

At least 40% of Afghanistan's medicine imported illegally, union claims

New damning allegations have arisen concerning Afghanistan’s pharmaceutical industry, as the Medicine Importers Union claims that at least 40% of the nation’s drug products are imported illegally.

Beyond the shocking figure, it is reported that a significant percentage of drugs in the country are of sub-par quality. The total sales of products imported into the country legitimately are estimated to be worth $700 million annually.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches